Moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy. Monotherapy or in combination w/ MTX in adults w/ active psoriatic arthritis (PsA). Moderate to severe active Crohn's disease in adults who have failed or were intolerant to immunomodulators, corticosteroids or ≥1 anti-TNF treatment, or were corticosteroid-dependent. Moderately to severe active ulcerative colitis in adults.
SCPlaque psoriasis, PsA 45 mg administered at wk 0 & 4, then every 12 wk thereafter. Alternatively, 90 mg in patient >100 kg. IVCrohn's disease & ulcerative colitisPatient >85 kg 520 mg as single IV dose, followed by 90 mg SC 8 wk later, then every 8 wk thereafter, >55 kg to ≤85 kg 390 mg as single IV dose, followed by 90 mg SC 8 wk later, then every 8 wk thereafter, ≤55 kg 260 mg as single IV dose, followed by 90 mg SC 8 wk later, then every 8 wk thereafter.
Discontinue use if anaphylactic or other serious hypersensitivity reaction occurs. Serious bacterial, fungal & viral infections; not to be given in patients w/ clinically important, active infection; caution w/ use in patients w/ chronic infection or history of recurrent infection. Evaluate patients for Tb prior to treatment; not to be given in patients w/ active Tb; treat latent Tb prior to treatment. Potential to increase malignancy; patients w/ history of malignancy; monitor for appearance of non-melanoma skin cancer in patients w/ medical history of prolonged immunosuppressant therapy or those w/ history of PUVA treatment. Not to be concurrently given w/ live viral or bacterial vaccines. Combination w/ immunosuppressive agents or phototherapy; allergy immunotherapy. Transitioning from other biologic agents. Latex sensitivity. Renal & hepatic impairment. Pregnancy & lactation. Childn <12 yr. Elderly ≥65 yr.
Sign Out
